Cardiac Myosin Inhibition: Remodeling Clinical Workflows in oHCM and Beyond |
|
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024. Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through an educational grant from Bristol Myers Squibb. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Milind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics. Co-Chair/Planner Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below. |